GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Expectations diminished as a result of numerous failed replications, the retraction of several previously reported positive replications, and the identification of methodological flaws and experimental errors in the original study. By late 1989, most scientists considered cold fusion claims dead, and cold fusion subsequently gained a reputation as pathological science. In 1989 the United States Department of Energy (DOE) concluded that the reported results of excess heat did not present convincing evidence of a useful source of energy and decided against allocating funding specifically for cold fusion. A second DOE review in 2004, which looked at new research, reached similar conclusions and did not result in DOE funding of cold fusion. Presently, since articles about cold fusion are rarely published in peer-reviewed mainstream scientific journals, they do not attract the level of scrutiny expected for mainstream scientific publications. Some interest in cold fusion has continued through the decades—for example, a Google-funded failed replication attempt was published in a 2019 issue of Nature. A small community of researchers continues to investigate it, often under the alternative designations low-energy nuclear reactions (LENR) or condensed matter nuclear science (CMNS).
Pure culture yeasts that are grown in a lab are often freeze dried and packaged for commercial use. Prior to their addition into must, these yeasts need to be re-hydrated in "starter cultures" that must be carefully monitored (particularly in regards to temperature) to ensure that the yeast cells are not killed off by cold shock. Ideally winemakers want to add enough inoculum to have a viable cell population density of 5 million cells per milliliter. The exact amount of freeze-dried culture varies by manufacturer and strain of yeast but it is often around 1 gram per gallon (or 25 grams per 100 liters). Wines that could have potentially problematic fermentation (such as high sugar level late harvest or botryized wines) may have more yeast added. Similarly, re-hydration procedures will also vary depending on the manufacturer and winery. Yeast is often inoculated in a volume of water or grape must that is 5–10 times the weight of the dry yeast. This liquid is often brought to temperature of 40 °C (104 °F) prior to the introduction of the yeast (though some yeast strains may need temperatures below 38 °C (100 °F)) to allow the cells to disperse easily rather than clump and sink to the bottom of the container. The heat activation also allows the cells to quickly reestablish their membrane barrier before soluble cytoplasmic components escape the cell. Re-hydration at lower temperatures can greatly reduce the viability of the yeast with up to 60% cell death if the yeast is re-hydrated at 15 °C (59 °F).
Wi-Fi uses channels in the 2.4 GHz and 5 GHz ISM bands with OFDM (orthogonal frequency-division multiplexing) modulation to transmit data at high rates. The transmitters in Wi-Fi modems are limited to a radiated power of 200 mW to 1 watt, depending on country. They have a maximum indoor range of about 150 ft (50 m) on 2.4 GHz and 50 ft (20 m) on 5 GHz. Wireless WAN (wireless wide area network, WWAN) – a variety of technologies that provide wireless internet access over a wider area than Wi-Fi networks do – from an office building to a campus to a neighborhood, or to an entire city. The most common technologies used are: cellular modems, that exchange computer data by radio with cell towers; satellite internet access; and lower frequencies in the UHF band, which have a longer range than Wi-Fi frequencies. Since WWAN networks are much more expensive and complicated to administer than Wi-Fi networks, their use so far has generally been limited to private networks operated by large corporations. Bluetooth – a very short-range wireless interface on a portable wireless device used as a substitute for a wire or cable connection, mainly to exchange files between portable devices and connect cellphones and music players with wireless headphones. In the most widely used mode, transmission power is limited to 1 milliwatt, giving it a very short range of up to 10 m (30 feet).
== Nanotechnology applications == Many potential applications have been suggested in literature, including enzyme immobilization, drug delivery systems, and nanotechnological self-assembly of materials. Though DNA is not the natural choice for building active structures for nanorobotic applications, due to its lack of structural and catalytic versatility, several papers have examined the possibility of molecular walkers on origami and switches for algorithmic computing. The following paragraphs list some of the reported applications conducted in the laboratories with clinical potential. In a study conducted by a group of scientists from iNANO center and CDNA Center at Aarhus university, researchers were able to construct a small multi-switchable 3D DNA Box Origami. The proposed nanoparticle was characterized by AFM, TEM and FRET. The constructed box was shown to have a unique reclosing mechanism, which enabled it to repeatedly open and close in response to a unique set of DNA or RNA keys. The authors proposed that this "DNA device can potentially be used for a broad range of applications such as controlling the function of single molecules, controlled drug delivery, and molecular computing."
Sources: en.wikipedia.org
== Release == To promote Half-Life, Valve's chief marketing officer, Monica Harrington, promoted Valve's reputation in the industry, with conference talks about their advances in game development, leading to coverage in the Wall Street Journal. Half-Life was released on November 19, 1998. When Sierra told Valve it was not planning to promote it beyond launch, Harrington threatened that Valve would "walk away from our agreement and tell the industry that had fallen in love with Valve how screwed up Sierra really was". In response, Sierra reissued Half-Life in a "Game of the Year" edition, boosting sales. In 2001, after renegotiating with Sierra, Valve gained the Half-Life intellectual property and online distribution rights for its games. Valve released two Half-Life demos. The first, Half-Life: Day One, contained the first fifth of the game and was distributed with certain graphic cards. The second, Half-Life: Uplink, was released on February 12, 1999, and featured original content. A short film based on Half-Life, also titled Half-Life: Uplink, was developed by Cruise Control, a British marketing agency, and released on February 11. The protagonist is a journalist who infiltrates the Black Mesa Research Facility, trying to discover what has happened there. Half-Life was censored in Germany to comply with the Federal Department for Media Harmful to Young Persons, which regulates depictions of violence against humans. Valve replaced the human characters with robots, spilling oil and gears instead of blood and body parts when killed, among other changes.
== Actinide partitioning: complexation mechanism == The selective separation of actinides from the PUREX raffinate by advanced processes needs new extracting agents, which must possess a more pronounced affinity towards actinides over lanthanides and other products mostly present in the acidic fuel dissolution. The design and the synthesis of efficient extracting agents rely on a deep knowledge of the complexation mechanism involved in the extraction process. Moreover, the structure and the stability of the ligand complexes with An(III) and Ln(III) upon extraction process, and the ligand selectivity need to be investigated. Research is being devoted to design more N-donor extracting agents, which show promising selectivity towards actinides.
The plant would be capable of converting natural gas into a liquid form that can be trucked to consumers. The project will create between 700 and 2,800 jobs in the region. In May 2019, Minister McNaughton announced that the Ontario government "committed up to $63.7 million" to Southwestern Integrated Fibre Technology (SWIFT) with support from other levels of government. The not-for-profit, publicly-funded SWIFT project to develop a regional fibre optic network, has been one of the key initiatives of the Western Ontario Wardens' Caucus (WOWC) representing upper-tier municipalities in southern Ontario from Dufferin to Windsor. Through SWIFT, federal, provincial and local municipalities "subsidize the construction of an open-access, high-speed broadband network in Southwestern Ontario, Caledon and the Niagara Region." In December 2025, Ford and Niagara Falls mayor Jim Diodati announced a new tourism strategy for the city, including expanded transportation and entertainment offerings such as new "attractions, gaming, wine and restaurants, and arts and culture." In early 2026, Ford announced plans to build a new 2-million square foot convention centre in Toronto, replacing the Metro Toronto Convention Centre. He later also announced plans to take control of the Billy Bishop Toronto City Airport to expand its runway and allow jets at the island airport, a suggestion immediately supported by the Toronto Port Authority. Expansion remains opposed by local Councillors, local community associations and the "NoJetsTo" and "Parks Not Planes" advocacy groups.
As of 2025, GeneDx has contributed to more than 1,100 peer-reviewed publications and contributes to more than 500 validated gene-disease associations through the GeneMatcher platform. In 2026, GeneDx researchers published a validation study in Human Genetics describing Multiscore, an AI-powered gene prioritization tool, that combines machine learning with real-world clinical data from the GeneDx database alongside published literature and OMIM, correctly prioritized the causative gene within the top 10 candidates in 83.5% of cases, outperforming existing phenotype-based prioritization tools including Phrank and LIRICAL. A 2026 real-world health economics analysis (SAVES-Kids), presented at the American College of Medical Genetics (ACMG) annual meeting, found GeneDx's exome and genome sequencing reduced total healthcare costs by up to 61% in the 12 months following testing for children with neurodevelopmental disorders. For children with epilepsy, that represents an average of approximately $80,000 per patient per year.
RNA, in contrast, forms large and complex 3D tertiary structures reminiscent of proteins, as well as the loose single strands with locally folded regions that constitute messenger RNA molecules. Those RNA structures contain many stretches of A-form double helix, connected into definite 3D arrangements by single-stranded loops, bulges, and junctions. Examples are tRNA, ribosomes, ribozymes, and riboswitches. These complex structures are facilitated by the fact that RNA backbone has less local flexibility than DNA but a large set of distinct conformations, apparently because of both positive and negative interactions of the extra OH on the ribose. Structured RNA molecules can do highly specific binding of other molecules and can themselves be recognized specifically; in addition, they can perform enzymatic catalysis (when they are known as "ribozymes", as initially discovered by Tom Cech and colleagues).
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.